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Objectives We sought to best estimate the benefits and risks associated with rescue percutaneous coronary intervention
(PCI) and repeat fibrinolytic therapy as compared with conservative management in patients with failed fibrino-
lytic therapy for ST-segment myocardial infarction (STEMI).
Background Fibrinolytic therapy is the most common treatment for STEMI; however, the best therapy in patients who fail to
achieve reperfusion after fibrinolytic therapy remains uncertain.
Methods We performed a meta-analysis of randomized trials using a fixed-effects model. We included 8 trials enrolling
1,177 patients with follow-up duration ranging from hospital discharge to 6 months.
Results Rescue PCI was associated with no significant reduction in all-cause mortality (relative risk [RR] 0.69; 95% con-
fidence interval [CI] 0.46 to 1.05), but was associated with significant risk reductions in heart failure (RR 0.73;
95% CI 0.54 to 1.00) and reinfarction (RR 0.58; 95% CI 0.35 to 0.97) when compared with conservative treat-
ment. Rescue PCI was associated with an increased risk of stroke (RR 4.98; 95% CI 1.10 to 22.5) and minor
bleeding (RR 4.58; 95% CI 2.46 to 8.55). Repeat fibrinolytic therapy was not associated with significant im-
provements in all-cause mortality (RR 0.68; 95% CI 0.41 to 1.14) or reinfarction (RR 1.79; 95% CI 0.92 to 3.48),
but was associated with an increased risk for minor bleeding (RR 1.84; 95% CI 1.06 to 3.18).
Conclusions Rescue PCI is associated with improved clinical outcomes for STEMI patients after failed fibrinolytic therapy, but
these benefits must be interpreted in the context of potential risks. On the other hand, repeat fibrinolytic therapy
is not associated with significant clinical improvement and may be associated with increased harm. (J Am Coll
Cardiol 2007;49:422–30) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.09.033n
a
p
t
a
1
p
U
b
E
S
r
R
S
F
flinical outcomes of patients with ST-segment elevation
yocardial infarction (STEMI) are strongly dependent on
he patency in the infarct-related artery after reperfusion
herapy (1,2). Despite potential advantages of primary
ercutaneous coronary intervention (PCI), fibrinolytic ther-
py remains the most common therapy for STEMI in the
.S. and worldwide (3–5). Fibrinolytic therapy restores
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ngiographically at 90 min, with even less success in elderly
atients and in those with cardiogenic shock (6–9). Given
hat one-half of the 500,000 STEMI patients treated
nnually in the U.S. receive fibrinolytic therapy, almost
25,000 patients a year will have suboptimal reperfusion and
oorer outcomes (4,10).
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January 30, 2007:422–30 Meta-Analysis of Rescue Angioplasty/FibrinolysisThe most appropriate treatment strategy for STEMI
atients who fail fibrinolytic therapy is uncertain. Recent
ractice guidelines for STEMI recommend rescue PCI as a
otential therapy for patients who fail fibrinolytic therapy;
owever, this recommendation is based primarily on expert
pinions and consensus (10,11). The lack of convincing data
n how to treat STEMI patients who fail fibrinolytic
herapy is reflected by the inconsistency in clinical practice
here conservative therapy with no further reperfusion
reatment, repeat fibrinolytic therapy, and rescue PCI are all
eing used commonly (12).
Two recent studies have provided new insights into the
reatment strategies for STEMI patients who fail fibrino-
ytic therapy (13). The REACT (Rescue Angioplasty versus
onservative Treatment or Repeat Thrombolysis) trial
emonstrated that rescue PCI is associated with an im-
rovement in the composite end point of death, reinfarc-
ion, stroke, or severe heart failure, when compared with
epeat fibrinolytic therapy or conservative management (13).
owever, this benefit was driven predominantly by a reduc-
ion in reinfarction, with no difference in survival between
reatment strategies. Moreover, this trial was terminated
rematurely, before complete enrollment, raising concerns
bout the true estimate of benefits (13,15). A second
ontemporary study, the MERLIN (Middlesbrough Early
evascularization to Limit Infarction) trial did not show
ignificant reduction of the primary end point of all-cause
ortality associated with rescue PCI when compared with
onservative therapy (14). Furthermore, in both trials,
atients treated with rescue PCI had increased bleeding, an
mportant predictor of poor long-term outcome (13,14,16).
We designed a meta-analysis of randomized trials com-
aring rescue PCI or repeat fibrinolytic therapy with con-
ervative therapy to provide the best estimate of benefits and
isks associated with these competing rescue strategies.
ethods
tudy identification. Relevant published studies were
dentified through a computerized literature search of the
ochrane library, EMBASE, and MEDLINE electronic
atabases from January 1966 to February 2006, using the
erms angioplasty, percutaneous coronary intervention, myocar-
ial infarction, thrombolytic therapy, fibrinolytic therapy, and
reatment failure. OVID search software (OVID, New York,
ew York) was utilized using the “exploded” search feature
17). In addition, bibliographies of journal articles, and
elevant reviews were extensively hand-searched to locate
dditional studies. No attempt was made to contact authors
or primary or missing data. Relevance for inclusion in the
ystematic review for both English and non-English publi-
ations was determined using a hierarchical approach based
n title, abstract, and the published manuscript (18).
tudy selection. Two investigators (H.C.W. and R.V.)
ndependently evaluated studies for possible inclusion. Any
isagreements were resolved by consensus. We included Sandomized trials that enrolled
TEMI patients who had failed
brinolytic therapy and com-
ared a strategy of either rescue
CI or repeat fibrinolytic therapy
ith conservative therapy. Con-
ervative therapy was defined as
o further immediate reperfusion
herapy. We accepted either an-
iographic or clinical definitions
or failed fibrinolytic therapy.
ngiographic failure was defined
y the Thrombolysis In Myocar-
ial Infarction (TIMI) perfusion
rade in the infarct-related epi-
ardial artery at the time of angiography. The presence of
ither an occluded infarct related artery (TIMI flow grade 0
r 1) or an artery with impaired flow (TIMI flow grade 2)
as accepted as evidence of failed fibrinolytic therapy
19–22). Clinical failure was defined by the lack of ST-
egment resolution at a set time after fibrinolytic therapy
13,14). Although definitions of reperfusion varied slightly
etween trials, each trial ascertained the failure of fibrino-
ytic therapy in an identical fashion for its participants.
Study quality was evaluated based on the 5-point scale
utlined by Jadad et al. (23), with criteria for: randomization
ith proper concealment of the allocation sequence, blind-
ng of the patient and investigator to treatment allocation
ith description of the blinding method, and completeness
f follow-up (23).
utcomes. Clinical efficacy outcomes of interest included
ll-cause mortality, heart failure, and reinfarction. Safety
utcomes abstracted included stroke, major bleeding, and
inor bleeding. We accepted the original study definitions
or all efficacy and safety end points. Although the assess-
ent of clinical outcomes among the trials was not stan-
ardized, within each trial the same criteria were applied
qually to the treatment groups.
tatistical analysis. A fixed-effects model based on the
antel-Haenszel method for combining results from the
ndividual trials was used. Summary relative risk (RR) ratios
nd 95% confidence intervals (CI) were calculated, as was
he pooled estimate of absolute risk reduction. Number
eeded to treat (NNT) and number needed to harm were
erived from the latter. Tests of heterogeneity were calcu-
ated by the Mantel-Haenszel method. Statistically signifi-
ant heterogeneity was not detected in any of the efficacy or
afety end points for either rescue PCI or repeat fibrinolytic
herapy.
Sensitivity analyses were conducted to examine the ro-
ustness of our results. For mortality, we eliminated 1 study
t a time from the analysis to determine if the pooled
stimates were disproportionately influenced by a particular
rial. In addition, we explored the efficacy of rescue PCI in
tudies where failed fibrinolytic therapy was defined by
Abbreviations
and Acronyms
CI  confidence interval
NNT  number needed to
treat
PCI  percutaneous
coronary intervention
RR  relative risk
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial InfarctionT-segment resolution alone. Statistical significance was set
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Meta-Analysis of Rescue Angioplasty/Fibrinolysis January 30, 2007:422–30s a p value 0.05. All statistical calculations were per-
ormed with the use of RevMan 4.2 (Cochrane Collabora-
ion, Oxford, United Kingdom).
esults
tudy selection. The process of study selection and exclu-
ion is outlined in Figure 1. We excluded 2 randomized
tudies of rescue PCI because they were not restricted to
TEMI patients who failed fibrinolytic therapy (24,25). We
lso excluded 1 trial of repeat fibrinolytic therapy, because it
rial Design of Rescue PCI Trials
Table 1 Trial Design of Rescue PCI Trials
Trial Name Year
Randomized,
n Inclusion Criteria Follow-Up
REACT (13) 2005 285 50% ST-segment
resolution at
90min and
TIMI 3
6-month
MERLIN (14) 2004 307 50% ST-segment
resolution at
60min
30-day
RESCUE II (22) 2000 29 TIMI 2 30-day
RESCUE (20) 1994 151 TIMI 0/1 30-day
TAMI (21) 1994 108 TIMI 2 In-hospital
Belenkie et al. (19) 1992 28 TIMI 0 In-hospital
Only data for treatment arm shown; †Jadad score rates study quality to a maximum of 5, based
MERLINMiddlesbrough Early Revascularization to Limit Infarction trial; PCI percutaneous co
Figure 1 Process of Study Selection for Rescue PCI or Repeat
PCI  percutaneous coronary intervention.rial; RESCUE  Randomized Comparison of Rescue Angioplasty with Conservative Management of Pa
hrombolysis and Angioplasty in Myocardial Infarction Study; TIMI  Thrombolysis In Myocardial Infarctioid not report any clinical end points (26). Therefore, our
eta-analysis included 8 trials with 1,177 patients, of which
here were 6 trials that randomized 908 patients to rescue
CI or conservative therapy and 3 trials that randomized
10 patients to repeat fibrinolysis or conservative therapy
13,14,19–22,27,28).
escue PCI versus conservative therapy. STUDY DESIGN
ND QUALITY. Table 1 summarizes the study designs of the
rescue PCI trials. Time from initial fibrinolytic adminis-
ration to rescue PCI ranged from 77 min to 274 min. The
ean
ge,
rs
Women,
%
Anterior
Wall,
%
Symptom Onset
to Lytic,
min*
Symptom Onset
to Rescue PCI,
min*
Jadad
Score†
1 22 43 140 (95–220)‡ 414 (350–505)‡ 4
3 28 44 180120 327121 3
3 7 59 210156 294252 3
9 18 100 N/A 270110 3
7 19 41 17662 26871 2
8 56 56 180 25757 2
domization method, blinding, and completeness of follow-up; ‡interquartile range.
intervention; REACT Rescue Angioplasty versus Conservative Treatment or Repeat Thrombolysis
olytic Therapy Versus Conservative ManagementM
A
y
6
6
6
5
5
5
on ran
ronaryFibrintients with Early Failure of Thrombolysis for Acute Anterior Myocardial Infarction trial; TAMI 
n perfusion grade.
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January 30, 2007:422–30 Meta-Analysis of Rescue Angioplasty/FibrinolysisEACT trial defined clinical reperfusion as 50% ST-
egment resolution at 90 min after initial fibrinolytic ad-
inistration (13). The MERLIN trial defined clinical
eperfusion using the same criteria at 60 min (14). Median
ime from symptom onset to rescue PCI was 414 min in the
ERLIN trial and 327 min in the REACT trial; both
tudies enrolled patients at non-interventional facilities and
equired transfer for rescue PCI (13,14). There were 4 trials
hat used angiographic TIMI perfusion grade for inclusion
19–22). Follow-up durations in the trials ranged from
ospital discharge to 6 months.
The 5-point quality score of the included studies are
Figure 2 Efficacy End Points for Rescue PCI Versus Conservati
CI  confidence interval; MERLIN  Middlesbrough Early Revascularization to Limi
vention; REACT  Rescue Angioplasty versus Conservative Treatment or Repeat T
servative Management of Patients with Early Failure of Thrombolysis for Acute Ante
Angioplasty in Myocardial Infarction study.resented in Table 1. Follow-up was complete in all 6 trials. tLINICAL AND ADVERSE OUTCOMES OF RESCUE PCI. Res-
ue PCI was associated with no significant improvement in
ll-cause mortality compared with conservative therapy, de-
ned as no additional immediate reperfusion treatment (RR
.69; 95% CI 0.46 to 1.05; p 0.09) (Fig. 2). For heart failure,
escue PCI was associated with an RR reduction of 27% (RR
.73; 95% CI 0.54 to 1.00; p  0.05) and an absolute risk
eduction of 5% (95% CI 0% to 9%; p  0.05). Similarly, the
isk of reinfarction was significantly reduced with rescue PCI
RR 0.58; 95% CI 0.35 to 0.97; p  0.04; absolute risk
eduction 4%; 95% CI 0% to 9%; p  0.03) (Fig. 2).
In 3 trials (13,14,21) enrolling 700 patients that reported
erapy
ction trial; NNT  number needed to treat; PCI  percutaneous coronary inter-
lysis trial; RESCUE  Randomized Comparison of Rescue Angioplasty with Con-
yocardial Infarction trial; RR  relative risk; TAMI  Thrombolysis andve Th
t Infar
hrombo
rior Mhe composite end point of all-cause mortality, reinfarction,
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Meta-Analysis of Rescue Angioplasty/Fibrinolysis January 30, 2007:422–30nd heart failure, rescue PCI was associated with a signifi-
ant RR reduction of 28% (RR 0.72; 95% CI 0.59 to 0.88;
 0.001). Furthermore, there was an 11% absolute risk
eduction (95% CI 5% to 18%; p 0.001) in this composite
nd point with an incidence of 29.2% in the PCI arm and
1.0% in the conservative arm, leading to a NNT of 9.
ensitivity Analysis of the Effect of Rescue PCI orpeat Fibrinolytic Therapy on M rtality
Table 2 Sensitivity Analysis of the Effect of Rescue PCI orRepeat Fibrinolytic Therapy on Mortality
Trials
(n)
Patients
Analyzed
(n)
Mortality
RR (95% CI)
Rescue PCI
All trials 6 908 0.69 (0.46–1.05)
Restricted to trials that assessed
clinical reperfusion (REACT
and MERLIN)
2 592 0.68 (0.42–1.12)
Analysis of all studies except
REACT 5 623 0.82 (0.49–1.35)
MERLIN 5 601 0.59 (0.34–1.02)
RESCUE 5 757 0.72 (0.46–1.13)
RESCUE II 5 879 0.67 (0.44–1.02)
TAMI 5 800 0.64 (0.41–0.98)
Belenkie et al. 5 880 0.75 (0.48–1.15)
Repeat Fibrinolytic Therapy
All trials 3 410 0.69 (0.41–1.14)
Analysis of all studies except
REACT 2 127 0.28 (0.10–0.81)
Sarullo et al. 2 320 0.99 (0.55–1.80)
Mounsey et al. 2 373 0.67 (0.40–1.13)
Figure 3 Safety End Points for Rescue PCI Versus Conservative
NNH  number needed to harm. Other abbreviations as in Figure 2.(
I  confidence interval; PCI  percutaneous coronary intervention; RR  relative risk; other
bbreviations as in Table 1.In the 2 trials enrolling 592 patients that assessed stroke
s an outcome, the incidence of stroke was 3.4% (10 of 297)
n the rescue PCI arm and 0.7% (2 of 295) in the
onservative arm (absolute risk increase 3%; 95% CI 0% to
%; p  0.02) (Fig. 3) (13,14). This corresponded to an
ncreased RR of 4.98 (95% CI 1.10 to 22.5; p  0.04) for
troke associated with rescue PCI. Information was reported
n the severity of stroke for 7 of the 10 events in the rescue
CI arm; 1 stroke was fatal, and 2 resulted in long-term
isability (13,14,21). None of the strokes in the conservative
rm resulted in death or long-term disability.
Only the REACT trial reported the incidence of major
leeding, which was 2.7% in the rescue PCI arm and 3.5%
n the conservative arm (RR 0.78; 95% CI 0.21 to 2.86; p
.65) (13). Among the 620 patients for which minor
leeding data were available, the incidence of minor bleed-
ng was 16.6% in the PCI arm and 3.6% in the conservative
rm (absolute risk increase 13%; 95% CI 8% to 18%; p 
.001) (13,14,19). Rescue PCI was associated with a sig-
ificantly increased risk of minor bleeding (RR 4.58; 95%
I 2.46 to 8.55; p  0.001) compared with conservative
herapy (Fig. 3).
ENSITIVITY ANALYSES FOR MORTALITY IN RESCUE PCI. In
he REACT and MERLIN trials, which enrolled patients
sing only clinical reperfusion criteria, rescue PCI was
ssociated with a similar estimate for all-cause mortality
RR 0.68; 95% CI 0.42 to 1.12) as compared with our
verall pooled estimate (RR 0.69; 95% CI 0.46 to 1.05)
rapyTheTable 2). Furthermore, the point estimate for all-cause
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January 30, 2007:422–30 Meta-Analysis of Rescue Angioplasty/Fibrinolysisortality associated with rescue PCI versus conservative
herapy was not disproportionately influenced by any of the
trials included in the meta-analysis (Table 2).
epeat fibrinolytic therapy versus conservative therapy.
TUDY DESIGN AND QUALITY. The 3 trials included in the
epeat fibrinolytic therapy analysis are shown in Table 3.
he agent used for repeat fibrinolytic therapy was tissue-
ype plasminogen activator in all 3 trials (13,27,28). Infor-
ation on the method of random allocation generation was
rovided in all of the trials (Table 3) (13,27,28). Two trials
ad a double-blinded design; the REACT trial had only
linding of end-point adjudication. All 3 trials had complete
ollow-up, ranging from hospital discharge to 6 months.
LINICAL AND ADVERSE OUTCOMES OF REPEAT FIBRINO-
YTIC THERAPY. We only analyzed all-cause mortality and
einfarction as our clinical outcomes because heart failure
as only reported in 1 trial. Repeat fibrinolytic therapy was
ot associated with significant risk reduction in all-cause
ortality (RR 0.68; 95% CI 0.41 to 1.14; p  0.14) or
einfarction (RR 1.79; 95% CI 0.92 to 3.48; p  0.09) (Fig.
). The incidence of heart failure in the REACT trial was
% in the repeat fibrinolytic therapy arm and 7.8% in the
onservative arm.
Stroke was reported only in the REACT trial with 1
vent in the conservative arm and 1 event in the repeat
brinolytic therapy arm. Minor bleeding was significantly
ncreased with repeat fibrinolytic therapy versus conservative
herapy (RR 1.84; 95% CI 1.06 to 3.18; p  0.03), but no
ignificant difference in the risk of major bleeding was
bserved (RR 1.54; 95% CI 0.54 to 4.4; p  0.42) (Fig. 5).
ENSITIVITY ANALYSES FOR MORTALITY IN REPEAT FI-
RINOLYTIC THERAPY. The results of sensitivity analyses
valuating the impact of individual studies on the pooled
stimate of all-cause mortality are shown in Table 2. This
stimate was strongly influenced by the study of Sarullo et al.
28); with elimination of this trial that enrolled 90 patients, the
R for all-cause mortality was 0.99 (95% CI 0.55 to 1.8).
iscussion
his meta-analysis, which systematically reviewed the ex-
sting literature on treatment strategies for STEMI patients
ho fail fibrinolytic therapy, found that rescue PCI was
ssociated with significant risk reductions for heart failure
nd reinfarction. In addition, the overall absolute reduction
n the composite end point of all-cause mortality, heart
ailure, or reinfarction was substantial, requiring only 9
atients to be treated for benefit. Conversely, there was
nsufficient evidence to suggest that a strategy of repeat
brinolytic therapy was efficacious. Nonetheless, rescue PCI
as also associated with an increased risk of stroke and
inor bleeding. Our study lends support to the recommen-
ation of rescue PCI as the treatment of choice for STEMI
atients who fail fibrinolytic therapy, but cannot advocate
he use of repeat fibrinolytic therapy. The potential benefits Tr
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Meta-Analysis of Rescue Angioplasty/Fibrinolysis January 30, 2007:422–30f rescue PCI, however, must be interpreted in the context
f its risks.
Due to limited evidence regarding the best management
f STEMI patients who fail fibrinolytic therapy, practice
uidelines do not strongly support any particular rescue
trategy as the treatment of choice (10,11). This has
ranslated into significant diversity in the management of
Figure 4 Efficacy End Points for Repeat Fibrinolytic Therapy Ve
Abbreviations as in Figure 2.
Figure 5 Safety End Points for Repeat Fibrinolytic Therapy Vers
Abbreviations as in Figure 2.hese patients (12). In a 1996 survey of European physi-
ians, 45% of respondents favored conservative management
f patients who fail fibrinolytic therapy, 16% favored rescue
CI, 20% favored administration of an alternative fibrino-
ytic agent, and 16% favored a combination strategy (12).
ur study has addressed this gap in knowledge by rigorously
ooling all available evidence in a meta-analysis. Although
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January 30, 2007:422–30 Meta-Analysis of Rescue Angioplasty/Fibrinolysisur conclusions are based on 1,000 enrolled patients, this
s the most comprehensive assessment to date of treatment
trategies for STEMI patients who fail fibrinolytic therapy.
Among patients who fail fibrinolytic therapy, rescue PCI
as associated with consistent improvements in clinical
utcomes despite time delays from symptom onset to
reatment that ranged from 4.3 to 6.9 h. Moreover, these
enefits were observed in the MERLIN and REACT trials,
hich included patients that required transfer to institutions
ith interventional capacities (13,14). Median transfer time
as 85 min in the REACT trial (13). In contrast, Nal-
amothu et al. (29) found a door-to-door time of 120 min
mong transfer patients undergoing primary PCI in the
.S. This supports the fact that improved systems are
rgently needed if full benefits of rescue PCI are to be
ealized in transferred patients (30).
We also observed a significant 3% increase in the absolute
isk of stroke associated with rescue PCI. However, the
stimate had relatively wide CIs because it was based on
nly 10 events in the rescue PCI arm and 2 events in the
onservative therapy arm. Moreover, the pooled estimate
as driven predominantly by the MERLIN trial, in which
events (4.6%) occurred in patients randomized to rescue
CI. Interestingly, the majority of strokes in that trial were
hromboembolic rather than hemorrhagic, opposite to what
ne would expect given the heightened degree of anticoag-
lation associated with rescue PCI (14). To place these
gures in proper context, the rate of stroke was 1.1% in the
ecent meta-analysis on facilitated PCI, and 0.3% in pri-
ary PCI (31). Further understanding of stroke risk asso-
iated with rescue PCI is necessary in order to improve
atient safety.
We evaluated bleeding as a safety end point because it has
een demonstrated to be an important predictor of adverse
utcomes after PCI (16). Given the systemic fibrinolytic
tate, and the additional antiplatelet and antithrombin use
ith rescue PCI, it was reassuring that there was no excess
ajor bleeding. Instead, most bleeding associated with
escue PCI was minor and localized to the arterial puncture
ite. Regardless, the increase in the risk of minor bleeding
ssociated with rescue PCI was substantial, with an absolute
isk increase of 13%. These adverse outcomes underscore
he importance of vigilant monitoring of hemostasis and the
eed for experienced operators.
In contrast with the clinical benefits of rescue PCI, we
bserved no significant benefits of repeat fibrinolytic therapy
n all-cause mortality, reinfarction, or stroke. The point
stimate for mortality associated with repeat fibrinolytic
herapy was 0.69, but was disproportionately influenced by
study in which the mortality rate in the conservative arm
as excessively high at 28.8% (compared with mortality
ates of 12.7% in the REACT trial) (28). The lack of
ubstantial benefit is consistent with the properties of
brinolytic therapy in which achieving arterial patency is
ttenuated with time due to organization of the epicardial
rtery thrombus, making it more resistant to the fibrinolyticgent (32). As such, current evidence cannot advocate repeat
brinolytic therapy for the treatment of STEMI patients
ho have failed fibrinolytic therapy.
This study has several important limitations. First, de-
pite the absence of statistically significant heterogeneity,
here are substantial differences in the entrance criteria of
he included trials. This heterogeneity reflects the difficulty
n evaluating the degree of reperfusion without recourse to
ngiography, a major barrier to the adoption of a standard-
zed rescue policy for management of failed fibrinolytic
herapy (14). As a non-invasive surrogate of angiographic
eperfusion, ST-segment resolution has varying sensitivity
o predict clinical reperfusion (1,33,34). Despite uncertainty
s to the optimal means of assessing reperfusion, our study
uggests that there is an improvement in clinical outcome if
rescue PCI strategy is employed.
Second, our pooled estimates are based on 500 patients
andomized per arm reflecting the difficulty in recruiting
atients for trials in this area (13,35). The lack of power to
etect a statistically significant difference (calculated power
f 0.48 to detect 30% RR reduction) is the most likely
xplanation for why we did not find any improvement in
ll-cause mortality. Despite this, the trend for reduced
ll-cause mortality with rescue PCI is compelling given its
onsistency across varying assumptions in the sensitivity
nalysis. In addition, our estimates of benefit and harm
cross other clinical outcomes are robust and relevant as a
eans of guiding therapy.
In summary, this meta-analysis of randomized trials lends
upport to the use of rescue PCI for failed fibrinolytic
herapy in patients with STEMI. In contrast, repeat fibri-
olysis cannot be recommended based on the available
vidence. In order to further improve outcomes and mini-
ize risks, randomized trials should be performed to deter-
ine the most appropriate adjunctive pharmacotherapy in
atients undergoing rescue PCI.
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APPENDIX
or the efficacy and safety end point definitions,
lease see the online version of this article.
